Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.
Mesna is widely used for the prevention of cyclophosphamide-related hemorrhagic cystitis. It has been associated with hypersensitivity-like cutaneous and systemic reactions in adult patients. We report a series of children with malignant disease, who developed such reactions following mesna administration and discuss possible mechanisms and management issues.
Khaw
Seong L
SL
Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia.
Downie
Peter A
PA
Waters
Keith D
KD
Ashley
David M
DM
Heath
John A
JA
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002528:Cerebellar Neoplasms / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy; D015080:Mesna / Q000008:administration & dosage / Q000009:adverse effects*; D012516:Osteosarcoma / Q000188:drug therapy; D020011:Protective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D013125:Spinal Neoplasms / Q000188:drug therapy
D020011:Protective Agents; D003520:Cyclophosphamide; D015080:Mesna